睿知中国疾病研究地图
候选清单0

北京北京大学医学部

北京大学第一医院

Peking University First Hospital

在本站收录的 53 种疾病中,这家医院列在其中 32 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

官方链接已于 2026-11-08 打开核对。

联系这家医院

北京大学第一医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 肝细胞癌Hepatocellular carcinoma19 篇牵头论文牵头 2 项开放试验
  2. 胃癌Stomach cancer27 篇牵头论文牵头 1 项开放试验
  3. 肝母细胞瘤Hepatoblastoma0 篇牵头论文
  4. 骨肉瘤Osteosarcoma4 篇牵头论文牵头 1 项开放试验
  5. 胃肠道间质瘤Gastrointestinal stromal tumour2 篇牵头论文
  6. 神经母细胞瘤Neuroblastoma6 篇牵头论文
  7. 尤文肉瘤Ewing sarcoma1 篇牵头论文
  8. 多发性骨髓瘤Multiple myeloma17 篇牵头论文牵头 5 项开放试验
  9. 噬血细胞性淋巴组织细胞增生症Haemophagocytic lymphohistiocytosis1 篇牵头论文
  10. 血友病 AHaemophilia A1 篇牵头论文
  11. 非典型溶血性尿毒症综合征Atypical haemolytic uraemic syndrome2 篇牵头论文
  12. 视神经脊髓炎谱系疾病Neuromyelitis optica spectrum disorder1 篇牵头论文
  13. IgG4相关性疾病IgG4-related disease5 篇牵头论文
  14. 重症肌无力Myasthenia gravis3 篇牵头论文
  15. 抗 NMDA 受体脑炎Anti-NMDA receptor encephalitis1 篇牵头论文
  16. 大动脉炎Takayasu arteritis1 篇牵头论文
  17. 肝包虫病Hepatic echinococcosis1 篇牵头论文
  18. 特发性肺纤维化Idiopathic pulmonary fibrosis4 篇牵头论文
  19. 肌萎缩侧索硬化症Amyotrophic lateral sclerosis2 篇牵头论文
  20. 脊髓性肌萎缩症Spinal muscular atrophy1 篇牵头论文
  21. 法布雷病Fabry disease8 篇牵头论文
  22. 庞贝病Pompe disease1 篇牵头论文
  23. 杜氏肌营养不良Duchenne muscular dystrophy11 篇牵头论文
  24. 白塞病Behçet disease2 篇牵头论文
  25. Alport 综合征Alport syndrome8 篇牵头论文
  26. IgA 肾病IgA nephropathy65 篇牵头论文牵头 1 项开放试验
  27. 尼曼-匹克病 C 型Niemann–Pick disease type C0 篇牵头论文
  28. 原发性胆汁性胆管炎Primary biliary cholangitis0 篇牵头论文
  29. 原发性硬化性胆管炎Primary sclerosing cholangitis1 篇牵头论文
  30. 先天性巨结肠Hirschsprung disease1 篇牵头论文
  31. 遗传性大疱性表皮松解症Inherited epidermolysis bullosa5 篇牵头论文
  32. 家族性腺瘤性息肉病Familial adenomatous polyposis1 篇牵头论文

未列出的收录疾病:鼻咽癌、食管鳞状细胞癌、视网膜母细胞瘤、脊索瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、β 地中海贫血、血栓性血小板减少性紫癜、范可尼贫血、烟雾病、肝豆状核变性、胆道闭锁、肺淋巴管平滑肌瘤病、戈谢病、成骨不全症、先天性膈疝、遗传性血管性水肿、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 19 篇,占 0.1%。

牵头论文
19
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
2
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 3320222023: 4420232024: 8820242025: 332025

北京有 17 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下

这家医院参与的开放试验 3

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
    分期
    不分期
    开始
    2026-04
    登记号
    NCT07557225

    年龄 18 岁 至 未注明(登记的条件)

    牵头:北京大学第一医院北京

  2. 正在招募
    GPC3-Targeted PET Imaging of 18F-X12 in Hepatocellular Carcinoma
    分期
    不分期
    开始
    2026-08
    登记号
    NCT07795437

    年龄 18 岁 至 未注明(登记的条件)

    牵头:北京大学第一医院北京

  3. 正在招募
    DEB-TACE With Visualable Microspheres Versus PVA Microspheres for HCC
    分期
    不分期
    开始
    2023-12
    登记号
    NCT06190665

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:东南大学附属中大医院;另有 1 家列出的医院为研究中心北京、南京

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题局部治疗(消融、TACE、HAIC)复发与预后乙肝与肝硬化
论文中的科室影像/核医学科普外/肝胆胰外科风湿免疫科消化/肝病科
牵头的论文19
  1. Impact of altitude on hemoglobin dynamics and prognosis in patients with advanced hepatocellular carcinoma receiving antiangiogenic TKIs: A propensity score matched study.2025Cancer chemotherapy and pharmacology
  2. Baseline FIB-4 May Be a Risk Factor of Recurrence After SBRT in Patients With HBV-Related Small HCC.2025Cancer medicine免费全文
  3. Radiofrequency ablation with or without conventional transarterial chemoembolization for subcapsular versus nonsubcapsular hepatocellular carcinoma within Milan criteria: a propensity score-matched study.2025International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  4. Feasibility of novel intraoperative navigation for anatomical liver resection using real-time virtual sonography combined with indocyanine green fluorescent imaging technology.2024Bioscience trends
  5. No Incidence of Liver Cancer Was Observed in A Retrospective Study of Patients with Aristolochic Acid Nephropathy.2024Chinese journal of integrative medicine
  6. Which is more appropriate for the evaluation of HCC, RECIST or mRECIST criteria?2024Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  7. Letter to the editor regarding "Comparing long-term survival benefits of hepatocellular carcinoma between thermal ablation monotherapy and combined therapy with transarterial chemoembolization: A propensity score matched study".2024European journal of radiology
  8. HDAC Inhibition Sensitize Hepatocellular Carcinoma to Lenvatinib via Suppressing AKT Activation.2024International journal of biological sciences免费全文
  9. Methodological challenges in studying immune-suppressive neutrophils in HCC models.2024Journal of hepatology
  10. Letter to the editor Re "Nomogram based on clinical and preoperative CT features for predicting the early recurrence of combined hepatocellular-cholangiocarcinoma: a multicenter study".2024La Radiologia medica
  11. Modifiable Risk Factors for Hepatocellular Carcinoma in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-Analysis.2024The American journal of medicine
  12. A case report of situs inversus totalis undergoing multiple interventional strategies.2023Asian journal of surgery
  13. Loadability and Releasing Profiles In Vitro and Pharmacokinetics In Vivo of Vinorelbine and Raltitrexed by CalliSpheres Beads.2023Cancer biotherapy & radiopharmaceuticals
  14. Factors associated with persistent positive in HBV DNA level in patients with chronic Hepatitis B receiving entecavir treatment.2023Frontiers in cellular and infection microbiology免费全文
  15. Smart nanoparticles and microbeads for interventional embolization therapy of liver cancer: state of the art.2023Journal of nanobiotechnology免费全文
  16. Long-term outcome of percutaneous radiofrequency ablation for periportal hepatocellular carcinoma: tumor recurrence or progression, survival and clinical significance.2022Cancer imaging : the official publication of the International Cancer Imaging Society免费全文
  17. Treatment response, survival and safety profile of transarterial chemoembolization using different sizes of drug-eluting beads in hepatocellular carcinoma patients with portal vein tumor thrombus.2022Clinics and research in hepatology and gastroenterology
  18. Long-term outcomes of combined transarterial chemoembolization and radiofrequency ablation versus RFA monotherapy for single hepatocellular carcinoma ≤3 cm: emphasis on local tumor progression.2022International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  19. Genome-wide association study identifies new loci associated with risk of HBV infection and disease progression.2021BMC medical genomics免费全文
中文论文(未计入)2
  1. [Expression of YARS1 in hepatocellular carcinoma and its prognostic effect].2025Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
  2. [Occurrence and recurrence of hepatitis C-related hepatocellular carcinoma after direct antiviral treatment].2022Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)5
  1. GPC3-Targeted PET Imaging of 18F-X12 in Hepatocellular Carcinoma正在招募NCT07795437牵头方不分期2026-08 启动
  2. 18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors正在招募NCT07557225牵头方不分期2026-04 启动
  3. DEB-TACE With Visualable Microspheres Versus PVA Microspheres for HCC正在招募NCT06190665研究中心不分期2023-12 启动
  4. A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma进行中,不再招募NCT04712643研究中心III期2021-03 启动
  5. Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)已完成NCT02112656研究中心III期2014-06 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 27 篇,占 0.3%。

牵头论文
27
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
3
由其他机构牵头
每年牵头的论文数
2021: 4420212022: 5520222023: 5520232024: 6620242025: 662025

北京有 15 家医院列在胃癌下全国有 218 家医院列在胃癌下

这家医院参与的开放试验 4

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    The Application of 18F-G1 PET/CT Targeting Granzyme B in the Pan-cancer Immunotherapy
    分期
    未注明
    开始
    2026-09
    登记号
    NCT07039474

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:北京大学第一医院北京

  2. 正在招募
    A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
    分期
    II期
    开始
    2025-02
    登记号
    NCT06760819

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 6 家列出的医院为研究中心上海、北京、杭州、长沙

  3. 正在招募
    Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
    分期
    未注明
    开始
    2025-02
    登记号
    NCT06846996

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 31 家列出的医院为研究中心上海、北京、南京、台州、天津、太原、广州、徐州、杭州、汕头、沈阳、海口、福州、郑州、长春

  4. 正在招募
    Combination of COMBO Endoscopy Oropharyngeal Airway and HFNC Oxygenation in Sedated Gastrointestinal Endoscopy for Morbidly Obese Patients
    分期
    不分期
    开始
    2025-10
    登记号
    NCT07175155

    年龄 18 岁 至 未注明(登记的条件)

    牵头:浙江大学医学院附属第一医院;另有 2 家列出的医院为研究中心北京、台州、杭州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题腹膜转移与晚期手术早期发现与内镜
论文中的科室普外/肝胆胰外科消化/肝病科影像/核医学科肿瘤内科
牵头的论文27
  1. Effectiveness of the aspiration method in preventing delayed bleeding after gastric endoscopic submucosal dissection.2026Surgical endoscopy免费全文
  2. Rapid and specific immunoPET imaging of Nectin-4 in gastric cancer and non-small cell lung cancer using [64Cu]Cu-NOTA-EV-F(ab')2.2025European journal of nuclear medicine and molecular imaging免费全文
  3. Preclinical evaluation of zirconium-89 labeled anti-Trop2 antibody-drug conjugate (Trodelvy) for imaging in gastric cancer and triple-negative breast cancer.2025European journal of nuclear medicine and molecular imaging免费全文
  4. Noninvasive Evaluation of Trop2 Expression Using 64Cu-NOTA-Trodelvy-F(ab')2 in Gastric and Pancreatic Cancer.2025Molecular pharmaceutics免费全文
  5. ImmunoPET Imaging of Nectin4 Expression in Gastric and Bladder Cancer Using [64Cu]Cu-NOTA-Padcev.2025Molecular pharmaceutics免费全文
  6. Prognostic value of neutrophil-lymphocyte ratio in gastroenteropancreatic neuroendocrine neoplasm: a systematic review and meta-analysis.2025PeerJ免费全文
  7. Evaluating the efficacy and safety of neoadjuvant immunochemotherapy versus chemotherapy in locally advanced gastric cancer undergoing radical gastrectomy: a retrospective study.2025World journal of surgical oncology免费全文
  8. Gastric metastasis from ovarian carcinoma diagnosed by EUS-FNB: A case report.2024Asian journal of surgery
  9. A solitary polyp of the stomach.2024Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  10. Cross-talk between Helicobacter pylori and gastric cancer: a scientometric analysis.2024Frontiers in cellular and infection microbiology免费全文
  11. Comparison of nasojejunal nutrition and intravenous nutrition supplementation in patients with upper gastrointestinal tract strictures and analysis of risk factors for malnutrition.2024Medicine免费全文
  12. Plasma metabolomics and lipidomics reveal potential novel biomarkers in early gastric cancer: An explorative study.2024The International journal of biological markers
  13. Short-and long-term outcomes of one-stage versus two-stage gastrectomy for perforated gastric cancer: a multicenter retrospective propensity score-matched study.2024World journal of surgical oncology免费全文
  14. LncRNA CCAT2 promotes malignant progression of metastatic gastric cancer through regulating CD44 alternative splicing.2023Cellular oncology (Dordrecht, Netherlands)免费全文
  15. Palliative Gastrectomy Improves the Survival of Patients with Metastatic Early-Onset Gastric Cancer: A Retrospective Cohort Study.2023Current oncology (Toronto, Ont.)免费全文
  16. A novel immunogenic cell death-related subtype classification and risk signature for predicting prognosis and immunotherapy efficacy in gastric cancer.2023Frontiers in immunology免费全文
  17. The BRD4 inhibitor JQ1 augments the antitumor efficacy of abemaciclib in preclinical models of gastric carcinoma.2023Journal of experimental & clinical cancer research : CR免费全文
  18. A convolutional neural network-based system for detecting early gastric cancer in white-light endoscopy.2023Scandinavian journal of gastroenterology
  19. LncRNA CRART16/miR-122-5p/FOS axis promotes angiogenesis of gastric cancer by upregulating VEGFD expression.2022Aging免费全文
  20. Value of Preoperative Hematological Parameters in the Prognosis of Gastric Cancer Patients Undergoing a Total Gastrectomy.2022Current medical science
  21. CAF promotes chemoresistance through NRP2 in gastric cancer.2022Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association免费全文
  22. Risk factors and characteristics of bacterial infection during first-line chemotherapy for metastatic gastric or gastroesophageal junction adenocarcinoma.2022Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  23. Survival benefits from neoadjuvant treatment in gastric cancer: a systematic review and meta-analysis.2022Systematic reviews免费全文
  24. Multivisceral resection for locally advanced gastric cancer: A retrospective study.2021American journal of surgery
  25. SPARC enhances 5-FU chemosensitivity in gastric cancer by modulating epithelial-mesenchymal transition and apoptosis.2021Biochemical and biophysical research communications
  26. An investigation on gastric cancer staging using CT structured report.2021European journal of radiology
  27. MiR-205-5p suppresses angiogenesis in gastric cancer by downregulating the expression of VEGFA and FGF1.2021Experimental cell research
中文论文(未计入)1
  1. [Pathological evaluation of endoscopic submucosal dissection for early gastric cancer and precancerous lesion in 411 cases].2023Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)8
  1. The Application of 18F-G1 PET/CT Targeting Granzyme B in the Pan-cancer Immunotherapy正在招募NCT07039474牵头方2026-09 启动
  2. Fuzheng Nizeng Formula for Chronic Atrophic Gastritis With Low-grade Intraepithelial Neoplasia, a Multicenter Randomized Controlled Trial状态不明NCT06324825牵头方不分期2022-10 启动
  3. Combination of COMBO Endoscopy Oropharyngeal Airway and HFNC Oxygenation in Sedated Gastrointestinal Endoscopy for Morbidly Obese Patients正在招募NCT07175155研究中心不分期2025-10 启动
  4. A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)正在招募NCT06760819研究中心II期2025-02 启动
  5. Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China正在招募NCT06846996研究中心2025-02 启动
  6. Comparing the Efficacy and Safety of Intra-peritoneal Infusion of Catumaxomab and Treatment of Investigator Choice in Patients With Advanced Gastric Carcinoma With Peritoneal Metastasis状态不明NCT04222114研究中心III期2020-10 启动
  7. Adjuvant Chemotherapy With S-1 Plus Oxaliplatin Versus S-1 Alone in Locally Advanced Gastric Cancer已终止NCT02867839研究中心III期2017-04 启动
  8. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric Cancer已完成NCT01839500研究中心2013-04 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

肝母细胞瘤

Hepatoblastoma

2021–2025 年没有牵头肝母细胞瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

北京有 9 家医院列在肝母细胞瘤下全国有 88 家医院列在肝母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肝母细胞瘤开放试验。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. [Therapeutic effect and clinical cost of multi-disciplinary team model of hepatoblastoma in children].2020Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.2%。

牵头论文
4
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 2220222023: 0020232024: 0020242025: 112025

北京有 48 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    68Ga-B7-H3 Nanobody ImmunoPET in Osteosarcoma
    分期
    早期I期
    开始
    2026-04
    登记号
    NCT07774533

    年龄 10 岁 至 80 岁(登记的条件)

    牵头:北京大学第一医院北京

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室儿科

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.4%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 1120242025: 002025

北京有 23 家医院列在胃肠道间质瘤下全国有 261 家医院列在胃肠道间质瘤下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
    分期
    II期
    开始
    2021-08
    登记号
    NCT04924075

    年龄 12 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心北京

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室影像/核医学科

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 6 篇,占 0.5%。

牵头论文
6
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 2220222023: 1120232024: 1120242025: 222025

北京有 24 家医院列在神经母细胞瘤下全国有 352 家医院列在神经母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。

这些数字背后的记录
论文中的科室儿科神经内科

这些论文过半是实验室或动物研究。

打开 PubMed 检索ClinicalTrials.gov

癌症

尤文肉瘤

Ewing sarcoma

2021–2025 年中国大陆作者发表的 163 篇尤文肉瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.6%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

北京有 17 家医院列在尤文肉瘤下全国有 139 家医院列在尤文肉瘤下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors
    分期
    I期
    开始
    2025-05
    登记号
    NCT06926283

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 4 家列出的医院为研究中心北京、杭州、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
牵头的论文1
  1. Primary ewing sarcoma in the uterine cervix with multiple bone metastases.2022Archives of gynecology and obstetrics
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors正在招募NCT06926283研究中心I期2025-05 启动
  2. Anlotinib and Irinotecan for Ewing Sarcoma状态不明NCT03416517研究中心I/II期2018-01 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 17 篇,占 1.0%。

牵头论文
17
2021–2025 年
牵头试验
6
任何状态,ClinicalTrials.gov
牵头的开放试验
5
正在或即将招募
作为研究中心的开放试验
6
由其他机构牵头
每年牵头的论文数
2021: 7720212022: 3320222023: 0020232024: 3320242025: 442025

北京有 15 家医院列在多发性骨髓瘤下全国有 178 家医院列在多发性骨髓瘤下

这家医院参与的开放试验 11

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    GPRC5D Targeted PET/CT Imaging in Plasma Cell Disorders
    分期
    I期
    开始
    2026-06
    登记号
    NCT07660939

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:北京大学第一医院北京

  2. 正在招募
    A Molecular Probe Targeting BCMA for the Clinical Diagnosis of Multiple Myeloma
    分期
    早期I期
    开始
    2025-04
    登记号
    NCT06717113

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:北京大学第一医院北京

  3. 正在招募
    68Ga-BCMA PET/CT in Multiple Myeloma
    分期
    II/III期
    开始
    2025-12
    登记号
    NCT07319897

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:北京大学第一医院;另有 2 家列出的医院为研究中心北京、石家庄、长春

  4. 正在招募
    PET Imaging Study of 68Ga-NB381 in Multiple Myeloma
    分期
    早期I期
    开始
    2024-04
    登记号
    NCT06385652

    年龄 18 岁 至 90 岁(登记的条件)

    牵头:北京大学第一医院北京

  5. 正在招募
    A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH
    分期
    未注明
    开始
    2021-07
    登记号
    NCT05283993

    年龄未注明(登记的条件)

    牵头:北京大学第一医院北京

  6. 正在招募
    A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
    分期
    III期
    开始
    2026-02
    登记号
    NCT07258511

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 9 家列出的医院为研究中心北京、南京、南宁、成都、杭州、武汉、温州、西安

  7. 正在招募
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    分期
    I期
    开始
    2026-05
    登记号
    NCT07477587

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 46 家列出的医院为研究中心上海、北京、南京、南昌、厦门、合肥、哈尔滨、天津、太原、宁波、广州、徐州、成都、无锡、杭州、武汉、沈阳、济南、深圳、温州、潍坊、石家庄、福州、苏州、蚌埠、贵阳、郑州、重庆、长沙、青岛

  8. 正在招募
    A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
    分期
    III期
    开始
    2026-05
    登记号
    NCT07518186

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 14 家列出的医院为研究中心北京、南京、南昌、天津、成都、杭州、武汉、深圳、温州、西安、长春

  9. 正在招募
    Long-term Follow-up Registry Study of Equecabtagene Autoleucel Injection
    分期
    未注明
    开始
    2024-12
    登记号
    NCT07028970

    年龄未注明(登记的条件)

    牵头方不是列出的医院;另有 5 家列出的医院为研究中心北京、天津、武汉、郑州

  10. 正在招募
    Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
    分期
    III期
    开始
    2022-09
    登记号
    NCT05243797

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、北京、天津、杭州、武汉、沈阳、济南、温州、郑州、长春

  11. 正在招募
    A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
    分期
    III期
    开始
    2022-10
    登记号
    NCT05552222

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 29 家列出的医院为研究中心上海、北京、南京、南宁、南昌、厦门、哈尔滨、天津、常州、广州、成都、杭州、武汉、沈阳、济南、深圳、温州、福州、西安、郑州、重庆、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题诊断、微小残留病与危险分层肾脏与骨骼并发症双抗与抗体药物
论文中的科室影像/核医学科病理/检验科
牵头的论文17
  1. Metabolomics and machine learning approaches for diagnostic biomarkers screening in systemic light chain amyloidosis.2025Annals of hematology免费全文
  2. CD38-specific immunoPET imaging for multiple myeloma diagnosis and therapeutic monitoring: preclinical and first-in-human studies.2025European journal of nuclear medicine and molecular imaging
  3. B-cell maturation antigen targeted PET/CT imaging in multiple myeloma: a first-in-human study.2025Journal of hematology & oncology免费全文
  4. Development and Preclinical Validation of a Novel 89Zr-Labeled BCMA-Targeting Antibody for ImmunoPET Imaging: Application in Multiple Myeloma Models and First-In-Nonhuman-Primates.2025Journal of medicinal chemistry
  5. Pharmacokinetic Positron Emission Tomography Imaging of an Optimized CD38-Targeted 68Ga-Labeled Peptide in Multiple Myeloma: A Pilot Study.2024Bioconjugate chemistry
  6. 5-Hydroxymethylcytosine Profiles of cfDNA in Urine as Diagnostic, Differential Diagnosis and Prognostic Markers for Multiple Myeloma.2024Cancer medicine免费全文
  7. Development of a Novel Peptide-Based PET Tracer [68Ga]Ga-DOTA-BP1 for BCMA Detection in Multiple Myeloma.2024Journal of medicinal chemistry
  8. Identification of CD8+ T-cell epitope from multiple myeloma-specific antigen AKAP4.2022Frontiers in immunology免费全文
  9. Prognostic Factors of AL-PCMM and AL-MM: A Single-Center Retrospective Study.2022International journal of medical sciences免费全文
  10. Clinical Characteristics and Prognosis of Multiple Myeloma With Myelomatous Pleural Effusion: A Retrospective Single-Center Study.2022Technology in cancer research & treatment免费全文
  11. Myeloma cast nephropathy with diffuse amyloid casts without systemic amyloidosis: two cases report.2021BMC nephrology免费全文
  12. Crystalline appearance in light chain cast nephropathy is associated with higher early mortality in patients with newly diagnosed multiple myeloma.2021International immunopharmacology
  13. Coexistent light chain deposition disease, light chain cast nephropathy, and vascular light chain amyloidosis in a patient with IgD lambda multiple myeloma.2021International urology and nephrology
  14. Contradictory Phenomenon Between Serum Separator Tube and Plasma Tube: A Case Report.2021Laboratory medicine
  15. Crystals in myeloma cast nephropathy.2021QJM : monthly journal of the Association of Physicians
  16. Crystalline light chain cast nephropathy in multiple myeloma.2021The Korean journal of internal medicine免费全文
  17. C3 glomerulonephritis along with light chain proximal tubulopathy without crystal deposits in multiple myeloma: a case report.2021World journal of surgical oncology免费全文
中文论文(未计入)2
  1. [Screening and Preliminary Validation of Multiple Myeloma Specific Proteins].2025Zhongguo shi yan xue ye xue za zhi
  2. [The indication of renal biopsy and novel understanding of pathological manifestations in multiple myeloma-related renal].2024Zhonghua nei ke za zhi
它在 ClinicalTrials.gov 上的全部试验(任何状态)22
  1. GPRC5D Targeted PET/CT Imaging in Plasma Cell Disorders正在招募NCT07660939牵头方I期2026-06 启动
  2. A Molecular Probe Targeting BCMA for the Clinical Diagnosis of Multiple Myeloma正在招募NCT06717113牵头方早期I期2025-04 启动
  3. 68Ga-BCMA PET/CT in Multiple Myeloma正在招募NCT07319897牵头方II/III期2025-12 启动
  4. PET Imaging Study of 68Ga-NB381 in Multiple Myeloma正在招募NCT06385652牵头方早期I期2024-04 启动
  5. A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH正在招募NCT05283993牵头方2021-07 启动
  6. A Clinical Study on the Whole-course Management (BCD-KPD-AutoHSCT) Scheme for Patients With RIMM状态不明NCT06203145牵头方不分期2024-01 启动
  7. A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma正在招募NCT07518186研究中心III期2026-05 启动
  8. A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma正在招募NCT07258511研究中心III期2026-02 启动
  9. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma正在招募NCT07477587研究中心I期2026-05 启动
  10. Long-term Follow-up Registry Study of Equecabtagene Autoleucel Injection正在招募NCT07028970研究中心2024-12 启动
  11. Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation正在招募NCT05243797研究中心III期2022-09 启动
  12. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma正在招募NCT05552222研究中心III期2022-10 启动
  13. A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide进行中,不再招募NCT06208150研究中心III期2024-01 启动
  14. A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)进行中,不再招募NCT06464991研究中心III期2024-03 启动
  15. A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment进行中,不再招募NCT05455320研究中心III期2022-10 启动
  16. A Study of Daratumumab进行中,不再招募NCT05438043研究中心III期2022-12 启动
  17. A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma进行中,不再招募NCT05083169研究中心III期2021-10 启动
  18. A Study of Ninlaro in Real World Clinical Practice in China已完成NCT04328662研究中心2020-05 启动
  19. A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1)状态不明NCT05066646研究中心I/II期2020-04 启动
  20. A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma进行中,不再招募NCT04557098研究中心II期2020-09 启动
  21. A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)已完成NCT03217812研究中心III期2017-11 启动
  22. A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma已完成NCT03234972研究中心III期2017-11 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

噬血细胞性淋巴组织细胞增生症

Haemophagocytic lymphohistiocytosis

2021–2025 年中国大陆作者发表的 399 篇噬血细胞性淋巴组织细胞增生症 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.2%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

北京有 11 家医院列在噬血细胞性淋巴组织细胞增生症下全国有 66 家医院列在噬血细胞性淋巴组织细胞增生症下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的噬血细胞性淋巴组织细胞增生症开放试验。

这些数字背后的记录
研究主题治疗方案淋巴瘤及肿瘤相关噬血

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血友病 A

Haemophilia A

2021–2025 年中国大陆作者发表的 272 篇血友病 A PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

北京有 15 家医院列在血友病 A下全国有 160 家医院列在血友病 A下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血友病 A开放试验。

这些数字背后的记录
牵头的论文1
  1. Peripheral Blood Lymphocyte Subsets in Factor VIII Inhibitor-Positive Patients with Severe Hemophilia A: A Case-Control Study.2024Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
中文论文(未计入)1
  1. [Pharmacokinetic Study of Coagulation Factor Ⅷ in Adults with Severe Hemophilia A].2024Zhongguo shi yan xue ye xue za zhi

打开 PubMed 检索ClinicalTrials.gov

血液疾病

非典型溶血性尿毒症综合征

Atypical haemolytic uraemic syndrome

2021–2025 年中国大陆作者发表的 27 篇非典型溶血性尿毒症综合征 PubMed 英文论文中,这家医院牵头了 2 篇,占 7.4%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 0020232024: 0020242025: 002025

北京有 6 家医院列在非典型溶血性尿毒症综合征下全国有 31 家医院列在非典型溶血性尿毒症综合征下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的非典型溶血性尿毒症综合征开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

视神经脊髓炎谱系疾病

Neuromyelitis optica spectrum disorder

2021–2025 年中国大陆作者发表的 485 篇视神经脊髓炎谱系疾病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.2%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

北京有 12 家医院列在视神经脊髓炎谱系疾病下全国有 67 家医院列在视神经脊髓炎谱系疾病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
    分期
    II/III期
    开始
    2024-07
    登记号
    NCT06413654

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 27 家列出的医院为研究中心北京、厦门、合肥、哈尔滨、天津、太原、广州、成都、昆明、杭州、武汉、沈阳、济南、温州、石家庄、福州、郑州、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题生物制剂预防复发急性发作治疗
论文中的科室儿科
牵头的论文1
  1. Meta-analysis of the effectiveness of relapse prevention therapy for myelin-oligodendrocyte glycoprotein antibody-associated disease.2023Multiple sclerosis and related disorders
中文论文(未计入)1
  1. [Clinical follow-up study of myelin oligodendrocyte glycoprotein antibody-associated disease in children].2021Zhonghua er ke za zhi = Chinese journal of pediatrics
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)正在招募NCT06413654研究中心II/III期2024-07 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgG4相关性疾病

IgG4-related disease

2021–2025 年中国大陆作者发表的 246 篇IgG4相关性疾病 PubMed 英文论文中,这家医院牵头了 5 篇,占 2.0%。

牵头论文
5
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 2220232024: 0020242025: 222025

北京有 11 家医院列在IgG4相关性疾病下全国有 46 家医院列在IgG4相关性疾病下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的IgG4相关性疾病开放试验。

这些数字背后的记录
研究主题肾脏、腹膜后与血管胰腺与胆管诊断与鉴别
论文中的科室神经内科肾内科影像/核医学科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

重症肌无力

Myasthenia gravis

2021–2025 年中国大陆作者发表的 499 篇重症肌无力 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.6%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 1120232024: 1120242025: 002025

北京有 11 家医院列在重症肌无力下全国有 93 家医院列在重症肌无力下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.
    分期
    II/III期
    开始
    2024-07
    登记号
    NCT06447597

    年龄 18 岁 至 70 岁(登记的条件)

    牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、北京、南昌、广州、成都、杭州、武汉、济南、西安、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题生物制剂与补体抑制剂常规免疫治疗抗体与诊断
论文中的科室神经内科
牵头的论文3
  1. COVID-19 in patients with myasthenia gravis: a single-center retrospective study in China.2024Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  2. Long-Term Efficacy and Safety of Low-Dose Rituximab in Patients with Refractory Myasthenia Gravis.2023European neurology
  3. Myasthenia gravis associated with renal cell carcinoma: a paraneoplastic syndrome or just a coincidence.2021BMC neurology免费全文
中文论文(未计入)1
  1. [Efficacy and safety of rituximab in the treatment of pediatric myasthenia gravis].2024Zhonghua er ke za zhi = Chinese journal of pediatrics
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.正在招募NCT06447597研究中心II/III期2024-07 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

抗 NMDA 受体脑炎

Anti-NMDA receptor encephalitis

2021–2025 年中国大陆作者发表的 264 篇抗 NMDA 受体脑炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

北京有 13 家医院列在抗 NMDA 受体脑炎下全国有 126 家医院列在抗 NMDA 受体脑炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的抗 NMDA 受体脑炎开放试验。

这些数字背后的记录
论文中的科室儿科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

大动脉炎

Takayasu arteritis

2021–2025 年中国大陆作者发表的 187 篇大动脉炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.5%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

北京有 30 家医院列在大动脉炎下全国有 108 家医院列在大动脉炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的大动脉炎开放试验。

这些数字背后的记录
牵头的论文1
  1. A 16-year-old girl with sudden heart failure and nephrotic syndrome associated with Takayasu's arteritis.2022Clinical research in cardiology : official journal of the German Cardiac Society
早期论文(2016–2020 年)1
  1. Unusual Collateral Vascular Development in a Patient with Takayasu Arteritis.2018Journal of vascular and interventional radiology : JVIR

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肝包虫病

Hepatic echinococcosis

2021–2025 年中国大陆作者发表的 152 篇肝包虫病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.7%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

北京有 6 家医院列在肝包虫病下全国有 49 家医院列在肝包虫病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肝包虫病开放试验。

这些数字背后的记录
论文中的科室普外/肝胆胰外科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.4%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 3320232024: 0020242025: 112025

北京有 27 家医院列在特发性肺纤维化下全国有 333 家医院列在特发性肺纤维化下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。

这些数字背后的记录
论文中的科室儿科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肌萎缩侧索硬化症

Amyotrophic lateral sclerosis

2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.3%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 1120242025: 002025

北京有 19 家医院列在肌萎缩侧索硬化症下全国有 194 家医院列在肌萎缩侧索硬化症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肌萎缩侧索硬化症开放试验。

这些数字背后的记录
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

脊髓性肌萎缩症

Spinal muscular atrophy

2021–2025 年中国大陆作者发表的 55 篇脊髓性肌萎缩症 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.8%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

北京有 8 家医院列在脊髓性肌萎缩症下全国有 51 家医院列在脊髓性肌萎缩症下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Phase I/II Clinical Study to Evaluate SKG0201 Injection in Subjects With Spinal Muscular Atrophy Type I
    分期
    I/II期
    开始
    2026-07
    登记号
    NCT07554924

    年龄 未注明 至 180 天(登记的条件)

    牵头方不是列出的医院;另有 3 家列出的医院为研究中心上海、北京、杭州

  2. 正在招募
    Safety and Efficacy Evaluation of GC101 Gene Therapy Via Intrathecal (IT) Injectionin the Treatment of Patients With Type 2 Spinal Muscular Atrophy (SMA) - Phase III
    分期
    III期
    开始
    2025-05
    登记号
    NCT06971094

    年龄 2 岁 至 12 岁(登记的条件)

    牵头方不是列出的医院;另有 6 家列出的医院为研究中心北京、武汉、深圳、苏州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室儿科
牵头的论文1
  1. A Post-Marketing Surveillance Study of Nusinersen for Spinal Muscular Atrophy in Routine Medical Practice in China: Interim Results.2024Advances in therapy
中文论文(未计入)1
  1. [Analysis of 4 children with DYNC1H1 gene related spinal muscular atrophy with lower extremity predominant 1].2023Zhonghua er ke za zhi = Chinese journal of pediatrics
它在 ClinicalTrials.gov 上的全部试验(任何状态)7
  1. A Phase I/II Clinical Study to Evaluate SKG0201 Injection in Subjects With Spinal Muscular Atrophy Type I正在招募NCT07554924研究中心I/II期2026-07 启动
  2. Safety and Efficacy Evaluation of GC101 Gene Therapy Via Intrathecal (IT) Injectionin the Treatment of Patients With Type 2 Spinal Muscular Atrophy (SMA) - Phase III正在招募NCT06971094研究中心III期2025-05 启动
  3. Efficacy and Safety of Intrathecal OAV101 (AVXS-101) in Pediatric Patients With Type 2 Spinal Muscular Atrophy (SMA)已完成NCT05089656研究中心III期2022-02 启动
  4. A Study to Learn About the Long-Term Safety of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Took Part in an Earlier Nusinersen Trial (ONWARD)已完成NCT04729907研究中心III期2021-04 启动
  5. Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy已完成NCT04089566研究中心III期2020-03 启动
  6. A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants已完成NCT02908685研究中心II期2016-10 启动
  7. Investigate Safety, Tolerability, PK, PD and Efficacy of Risdiplam (RO7034067) in Infants With Type1 Spinal Muscular Atrophy已完成NCT02913482研究中心II期2016-12 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

法布雷病

Fabry disease

2021–2025 年中国大陆作者发表的 73 篇法布雷病 PubMed 英文论文中,这家医院牵头了 8 篇,占 11.0%。

牵头论文
8
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 2220232024: 2220242025: 442025

北京有 11 家医院列在法布雷病下全国有 85 家医院列在法布雷病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease
    分期
    未注明
    开始
    2025-11
    登记号
    NCT07187440

    年龄 7 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 18 家列出的医院为研究中心北京、南京、合肥、哈尔滨、天津、太原、成都、杭州、汕头、深圳、石家庄、福州、苏州、西安

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室神经内科眼科/神经眼科
牵头的论文8
  1. The vestibular and oculomotor dysfunction in Fabry disease: a cohort study in China.2025Annals of medicine
  2. Elevated circulating cell-free mitochondrial DNA in fabry disease: insights into inflammatory activation.2025Frontiers in immunology
  3. Corneal neuro-immune crosstalk in Fabry disease: An in vivo confocal microscopic study.2025Journal of neuroimmunology
  4. Deep learning assisted retinal microvasculature assessment and cerebral small vessel disease in Fabry disease.2025Orphanet journal of rare diseases
  5. Inflammatory cytokine expression in Fabry disease: impact of disease phenotype and alterations under enzyme replacement therapy.2024Frontiers in immunology
  6. Evaluation of global and regional myocardial work by echocardiography in patients with Fabry disease.2024Orphanet journal of rare diseases
  7. Investigation of ocular involvement in patients with Fabry disease.2023Annals of medicine
  8. Brain MRI correlations with disease burden and biomarkers in Fabry disease.2023Journal of neurology
中文论文(未计入)1
  1. [Hypertrophic obstructive cardiomyopathy associated with Fabry disease: a case report].2025Zhonghua nei ke za zhi
早期论文(2016–2020 年)1
  1. Plasma lipidomic analysis of sphingolipids in patients with large artery atherosclerosis cerebrovascular disease and cerebral small vessel disease.2020Bioscience reports
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease正在招募NCT07187440研究中心2025-11 启动
  2. Study of the Safety and Biologic Activity of AL01211 in Treatment Naive Males With Classic Fabry Disease状态不明NCT06114329研究中心II期2023-10 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

庞贝病

Pompe disease

2021–2025 年中国大陆作者发表的 30 篇庞贝病 PubMed 英文论文中,这家医院牵头了 1 篇,占 3.3%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

北京有 6 家医院列在庞贝病下全国有 30 家医院列在庞贝病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的庞贝病开放试验。

这些数字背后的记录
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

杜氏肌营养不良

Duchenne muscular dystrophy

2021–2025 年中国大陆作者发表的 213 篇杜氏肌营养不良 PubMed 英文论文中,这家医院牵头了 11 篇,占 5.2%。

牵头论文
11
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 4420232024: 5520242025: 222025

北京有 11 家医院列在杜氏肌营养不良下全国有 116 家医院列在杜氏肌营养不良下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的杜氏肌营养不良开放试验。

这些数字背后的记录
论文中的科室神经内科儿科
牵头的论文11
  1. Interleukin-17B is a new biomarker of human muscle regeneration in dystrophinopathies.2025Brain : a journal of neurology
  2. RNA sequencing facilitates the identification of genetic causes of Duchenne muscular dystrophy and proposes a stepwise DMD diagnostic procedure.2025Gene
  3. Single-Nucleus RNA Sequencing Unravels Early Mechanisms of Human Becker Muscular Dystrophy.2024Annals of neurology
  4. Prevalence of Adeno-Associated Virus-9-Neutralizing Antibody in Chinese Patients with Duchenne Muscular Dystrophy.2024Human gene therapy
  5. A novel biomarker of fibrofatty replacement in dystrophinopathies identified by integrating transcriptome, magnetic resonance imaging, and pathology data.2024Journal of cachexia, sarcopenia and muscle
  6. A new pseudoexon activation due to ultrarare branch point formation in Duchenne muscular dystrophy.2024Neuromuscular disorders : NMD
  7. Clinical and genetic interpretation of uncertain DMD missense variants: evidence from mRNA and protein studies.2024Orphanet journal of rare diseases
  8. Cryptic exon activation caused by a novel deep-intronic splice-altering variant in Becker muscular dystrophy.2023Journal of clinical laboratory analysis
  9. Clinical, muscle imaging, and genetic characteristics of dystrophinopathies with deep-intronic DMD variants.2023Journal of neurology
  10. Clinical, pathological, and genetic characterization in a large Chinese cohort with female dystrophinopathy.2023Neuromuscular disorders : NMD
  11. Characteristics and feasibility of ambulatory respiratory assessment of paediatric neuromuscular disease: an observational retrospective study.2023The International journal of neuroscience
中文论文(未计入)2
  1. [Screening for Duchenne muscular dystrophy in newborns in the Ningxia region].2024Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
  2. [Clinical and genetic characteristics of 9 rare cases with coexistence of dual genetic diagnoses].2023Zhonghua er ke za zhi = Chinese journal of pediatrics
早期论文(2016–2020 年)4
  1. Long-read whole-genome sequencing for the genetic diagnosis of dystrophinopathies.2020Annals of clinical and translational neurology
  2. Splicing Characteristics of Dystrophin Pseudoexons and Identification of a Novel Pathogenic Intronic Variant in the DMD Gene.2020Genes
  3. T2 Mapping and Fat Quantification of Thigh Muscles in Children with Duchenne Muscular Dystrophy.2019Current medical science
  4. [Magnetic resonance imaging of dystrophinopathy that mimics adductor enthesopathy].2016Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Natural History Study In Chinese Male Patients With Duchenne Muscular Dystrophy已完成NCT03760029研究中心不分期2019-07 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

白塞病

Behçet disease

2021–2025 年中国大陆作者发表的 245 篇白塞病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.8%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 2220242025: 002025

北京有 24 家医院列在白塞病下全国有 149 家医院列在白塞病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease
    分期
    III期
    开始
    2023-11
    登记号
    NCT06145893

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 20 家列出的医院为研究中心上海、临沂、北京、南昌、厦门、太原、广州、徐州、杭州、桂林、深圳、温州、石家庄、苏州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
牵头的论文2
  1. Surgical intervention and management of Behcet disease with perianal abscess: A case report.2024Asian journal of surgery
  2. Behcet's-like disease induced by secukinumab in a patient with psoriasis: a case report and literature review.2024The Journal of dermatological treatment
早期论文(2016–2020 年)1
  1. [Panuveitis with oral and genital ulcer misdiagnosed as Behcet's disease: two cases report and literature review].2016Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease正在招募NCT06145893研究中心III期2023-11 启动
  2. A Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet Disease已终止NCT04609397研究中心II期2020-11 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

Alport 综合征

Alport syndrome

2021–2025 年中国大陆作者发表的 58 篇Alport 综合征 PubMed 英文论文中,这家医院牵头了 8 篇,占 13.8%。

牵头论文
8
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 1120222023: 3320232024: 1120242025: 112025

北京有 7 家医院列在Alport 综合征下全国有 60 家医院列在Alport 综合征下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的Alport 综合征开放试验。

这些数字背后的记录
论文中的科室儿科眼科/神经眼科
牵头的论文8
  1. A retrospective study of kidney disease in Alport syndrome during and after pregnancy.2025Journal of nephrology
  2. Characterization of Ocular Morphology in Col4a3-/- Mice as a Murine Model for Alport Syndrome.2024Translational vision science & technology
  3. Primary membranous nephropathy in two siblings with one combined with anti-glomerular basement membrane disease: a case report.2023BMC nephrology
  4. Genetic Variants of the COL4A3 , COL4A4 , and COL4A5 Genes Contribute to Thinned Glomerular Basement Membrane Lesions in Sporadic IgA Nephropathy Patients.2023Journal of the American Society of Nephrology : JASN
  5. Combined Alport syndrome, Klinefelter syndrome and Fanconi syndrome in a Chinese boy.2023Nephrology (Carlton, Vic.)
  6. A woman with Alport syndrome in compound-heterozygous state in pregnancy: lessons for the clinical nephrologist.2022Journal of nephrology
  7. Genotype-phenotype correlations and nephroprotective effects of RAAS inhibition in patients with autosomal recessive Alport syndrome.2021Pediatric nephrology (Berlin, Germany)
  8. mRNA analysis identifies deep intronic variants causing Alport syndrome and overcomes the problem of negative results of exome sequencing.2021Scientific reports
早期论文(2016–2020 年)12
  1. Reassessing the pathogenicity of c.2858G>T(p.(G953V)) in COL4A5 Gene: report of 19 Chinese families.2020European journal of human genetics : EJHG
  2. [Clinical phenotype of Alport syndrome in monozygotic twins].2020Zhonghua er ke za zhi = Chinese journal of pediatrics
  3. Dysregulated Expression of microRNA-21 and Disease-Related Genes in Human Patients and in a Mouse Model of Alport Syndrome.2019Human gene therapy
  4. Effect of heterozygous pathogenic COL4A3 or COL4A4 variants on patients with X-linked Alport syndrome.2019Molecular genetics & genomic medicine
  5. X-linked Alport syndrome: pathogenic variant features and further auditory genotype-phenotype correlations in males.2018Orphanet journal of rare diseases
  6. Urinary epidermal growth factor as a prognostic marker for the progression of Alport syndrome in children.2018Pediatric nephrology (Berlin, Germany)
  7. Renal, auricular, and ocular outcomes of Alport syndrome and their current management.2018Pediatric nephrology (Berlin, Germany)
  8. [Detection of large deletions in X linked Alport syndrome using competitive multiplex fluorescence polymerase chain reaction].2017Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  9. Accelerated podocyte detachment and progressive podocyte loss from glomeruli with age in Alport Syndrome.2017Kidney international
  10. Long-term treatment by ACE inhibitors and angiotensin receptor blockers in children with Alport syndrome.2016Pediatric nephrology (Berlin, Germany)
  11. [Analysis of diagnosis and treatment of Alport syndrome].2016Zhonghua er ke za zhi = Chinese journal of pediatrics
  12. [Clinical and genetic features of X-linked Alport syndrome in men positive for the collagen Ⅳ α5 chain in epidermal basement membrane].2016Zhonghua er ke za zhi = Chinese journal of pediatrics
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Study to Learn About How Well BAY 3401016 Works in Adults With Alport Syndrome进行中,不再招募NCT07211685研究中心II期2025-11 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 65 篇,占 8.8%。

牵头论文
65
2021–2025 年
牵头试验
5
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
8
由其他机构牵头
每年牵头的论文数
2021: 141420212022: 101020222023: 121220232024: 171720242025: 992025

北京有 32 家医院列在IgA 肾病下全国有 346 家医院列在IgA 肾病下

这家医院参与的开放试验 9

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    To Assess the Efficacy and Safety of Utilizing Galactose-deficient IgA1 Biomarker Changes to Guide Pathogenic IgA-targeted Therapeutic Strategies
    分期
    不分期
    开始
    2026-08
    登记号
    NCT07822100

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:北京大学第一医院北京

  2. 正在招募
    A Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy.
    分期
    I/II期
    开始
    2026-02
    登记号
    NCT07375758

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心北京

  3. 正在招募
    Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN
    分期
    III期
    开始
    2026-04
    登记号
    NCT07390123

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 9 家列出的医院为研究中心Huangshan City、上海、临沂、北京、湛江、芜湖、西安、长春、长沙

  4. 正在招募
    A Trial to Evaluate the Long-term Safety and Tolerability of HRS-5965 in Patients With Primary IgA Nephropathy
    分期
    II期
    开始
    2026-07
    登记号
    NCT07582133

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心北京

  5. 正在招募
    Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular Diseases
    分期
    II期
    开始
    2026-05
    登记号
    NCT07614477

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 2 家列出的医院为研究中心北京、天津

  6. 正在招募
    A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
    分期
    III期
    开始
    2025-07
    登记号
    NCT06963827

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 20 家列出的医院为研究中心上海、包头、北京、南京、南昌、南通、厦门、宁波、广州、成都、无锡、杭州、济南、深圳、珠海、长沙

  7. 正在招募
    A Trial of HRS-5965 Capsule in Primary IgA Nephropathy
    分期
    III期
    开始
    2025-06
    登记号
    NCT07014826

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心北京

  8. 正在招募
    A Study to Evaluate the Long-Term Safety and Efficacy of HSK39297 Tablets in Primary IgA Nephropathy
    分期
    II期
    开始
    2025-08
    登记号
    NCT07616700

    年龄未注明(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心北京

  9. 正在招募
    Clinical Study of CM338 in the Treatment of Immunoglobulin A Nephropathy
    分期
    II期
    开始
    2023-05
    登记号
    NCT05775042

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心北京

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室儿科肾内科
牵头的论文65
  1. The Association of Proteinuria Target Achievement Timing and Stability with Adverse Kidney Outcomes among Patients with IgA Nephropathy: A Cohort Study.2026American journal of nephrology
  2. CFHR3*B Haplotype, Complement Activation, and Risk of IgA Nephropathy.2026Journal of the American Society of Nephrology : JASN
  3. Genetic Determinants of Steroid Responsiveness in IgA Nephropathy.2026Journal of the American Society of Nephrology : JASNRCT
  4. New thoughts on the intestinal microbiome-B cell-IgA axis and therapies in IgA nephropathy.2025Autoimmunity reviews
  5. Expanding the spectrum of genetic causes of DNA-specific exonuclease TREX1 variants in thrombotic microangiopathy.2025Kidney international
  6. Red blood cell casts on kidney biopsy and progression of IgA nephropathy.2025Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  7. Long-term outcomes of IgA nephropathy in China.2025Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  8. Efficacy and Safety of Telitacicept in IgA Nephropathy: A Retrospective, Multicenter Study.2025Nephron
  9. Efficacy and safety of telitacicept in IgA nephropathy and IgA vasculitis nephropathy in adolescents: a case series.2025Pediatric nephrology (Berlin, Germany)
  10. Causal relationships between gut microbiota and IgA nephropathy: evidence from Mendelian randomization and microbiome validation.2025Renal failure
  11. Origin of poorly galactosylated IgA1 other than mucosa: a viewpoint from a report on patient with IgA vasculitis.2025Renal failure
  12. The evolving understanding of systemic mechanisms in organ-specific IgA nephropathy: a focus on gut-kidney crosstalk.2025Theranostics
  13. Time-Varying Proteinuria and Progression of IgA Nephropathy: A Cohort Study.2024American journal of kidney diseases : the official journal of the National Kidney Foundation
  14. Clinical Implications of C2 Lesion in IgA Nephropathy: A Cohort Study.2024American journal of nephrology
  15. Sunitinib-induced endocapillary proliferative glomerulonephritis with IgA2 deposit in addition to thrombotic microangiopathy: a case report.2024BMC nephrology
  16. Heterozygous mutations in factor H aggravate pathological damage in a stable IgA deposition model induced by Lactobacillus casei cell wall extract.2024Frontiers in immunology
  17. Unveiling biomarkers and therapeutic targets in IgA nephropathy through large-scale blood transcriptome analysis.2024International immunopharmacology
  18. A cluster of type I interferon-regulated genes associates with disease activity and prognosis in patients with IgA nephropathy.2024International immunopharmacology
  19. Circulating Proteins and IgA Nephropathy: A Multiancestry Proteome-Wide Mendelian Randomization Study.2024Journal of the American Society of Nephrology : JASN
  20. Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy.2024Kidney internationalRCT
  21. Efficacy and Safety of Nefecon in Patients with IgA Nephropathy from Mainland China: 2-Year NefIgArd Trial Results.2024Kidney360RCT
  22. Targeted release of budesonide in primary IgA nephropathy.2024Lancet (London, England)
  23. Low dose glucocorticoids, mycophenolate mofetil and hydroxychloroquine in IgA nephropathy, an update of current clinical trials.2024Nephrology (Carlton, Vic.)
  24. Current understanding and new insights in the treatment of IgA nephropathy.2024Nephrology (Carlton, Vic.)
  25. Association between urinary C4d levels and disease progression in IgA nephropathy.2024Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  26. Genetics of IgA nephrology: risks, mechanisms, and therapeutic targets.2024Pediatric nephrology (Berlin, Germany)
  27. Are children with IgA nephropathy different from adult patients?2024Pediatric nephrology (Berlin, Germany)
  28. Prognosis of IgA nephropathy patient with proteinuria remission by supportive therapy: cohort from screening failed Chinese patients in TESTING study.2024Renal failure
  29. The Genetics of IgA Nephropathy: Implications for Future Therapies.2024Seminars in nephrology
  30. Comparison between hydroxychloroquine and systemic corticosteroids in IgA nephropathy: a two-year follow-up study.2023BMC nephrology
  31. Mesangial C3 Deposition, Complement-Associated Variant, and Disease Progression in IgA Nephropathy.2023Clinical journal of the American Society of Nephrology : CJASN
  32. Machine learning in predicting T-score in the Oxford classification system of IgA nephropathy.2023Frontiers in immunology
  33. Global trends and hotspots in IgA nephropathy: a bibliometric analysis and knowledge map visualization from 2012 to 2023.2023International urology and nephrology
  34. The spectrum and changes of biopsy-proven kidney diseases in Chinese children.2023Journal of nephrology
  35. Genetic Variants of the COL4A3 , COL4A4 , and COL4A5 Genes Contribute to Thinned Glomerular Basement Membrane Lesions in Sporadic IgA Nephropathy Patients.2023Journal of the American Society of Nephrology : JASN
  36. MTMR3 risk alleles enhance Toll Like Receptor 9-induced IgA immunity in IgA nephropathy.2023Kidney international
  37. Glucocorticoids for IgA nephropathy-pro.2023Kidney international
  38. Intensive blood pressure control and the progression of IgA nephropathy: a cohort study using marginal structural models.2023Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  39. Corticosteroids in the treatment of IgA nephropathy: lessons from the TESTING trial.2023Pediatric nephrology (Berlin, Germany)
  40. Diagnosis and treatment of IgA nephropathy and IgA vasculitis nephritis in Chinese children.2023Pediatric nephrology (Berlin, Germany)
  41. Urinary epidermal growth factor predicts complete remission of proteinuria in Chinese children with IgA nephropathy.2023Pediatric research
  42. The clinical and pathological characteristics of IgA nephropathy patients in Tibet.2022BMC nephrology
  43. Concurrent IgA Nephropathy and Membranous Nephropathy, Is It an Overlap Syndrome?2022Frontiers in immunology
  44. Complement factor H variants are associated with microangiopathy lesions in IgA nephropathy.2022International immunopharmacology
  45. Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.2022JAMARCT
  46. The effect of immunosuppressive therapy in patients with fibrinoid necrosis lesions in a large cohort of patients with IgA nephropathy.2022Journal of nephrology
  47. Long-term safety and efficacy of hydroxychloroquine in patients with IgA nephropathy: a single-center experience.2022Journal of nephrology
  48. The efficacy and safety of hydroxychloroquine in pregnant patients with IgA nephropathy: A retrospective cohort study.2022Nephrology (Carlton, Vic.)
  49. The level of urinary C4d is associated with disease progression in IgA nephropathy with glomerular crescentic lesions: a cohort study.2022Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  50. Clinical and Pathological Features of Renal Presentations in Polycythemia Vera.2022The American journal of the medical sciences
  51. Sustained release of Lactobacillus casei cell wall extract can induce a continuous and stable IgA deposition model.2022The Journal of pathology
  52. Collectin11 and Complement Activation in IgA Nephropathy.2021Clinical journal of the American Society of Nephrology : CJASN
  53. Poly-IgA Complexes and Disease Severity in IgA Nephropathy.2021Clinical journal of the American Society of Nephrology : CJASN
  54. Exome Chip Analyses and Genetic Risk for IgA Nephropathy among Han Chinese.2021Clinical journal of the American Society of Nephrology : CJASN
  55. Potential Roles of Oral Microbiota in the Pathogenesis of Immunoglobin A Nephropathy.2021Frontiers in cellular and infection microbiology
  56. Complement Activation Is Associated With Crescents in IgA Nephropathy.2021Frontiers in immunology
  57. A Functional Variant rs3093023 in CCR6 Is Associated With IgA Nephropathy by Regulating Th17 Cells in a North Han Chinese Population.2021Frontiers in immunology
  58. Immune characteristics of renal allograft donors with mesangial IgA deposition.2021International immunopharmacology
  59. Urinary sediments could differentiate endocapillary proliferative lupus nephritis and endocapillary proliferative IgA nephropathy.2021International immunopharmacology
  60. Interaction between GALNT12 and C1GALT1 Associates with Galactose-Deficient IgA1 and IgA Nephropathy.2021Journal of the American Society of Nephrology : JASN
  61. Shared genetic study gives insights into the shared and distinct pathogenic immunity components of IgA nephropathy and SLE.2021Molecular genetics and genomics : MGG
  62. O-glycoforms of polymeric immunoglobulin A1 in the plasma of patients with IgA nephropathy are associated with pathological phenotypes.2021Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  63. Mass spectrometry-based screening identifies circulating immunoglobulinA-α1-microglobulin complex as potential biomarker in immunoglobulin A nephropathy.2021Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  64. Associations of ABO blood type and galactose-deficient immunoglobulin A1 with adverse outcomes in patients with IgA nephropathy.2021Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  65. Is IgA nephropathy the same disease in different parts of the world?2021Seminars in immunopathology
中文论文(未计入)5
  1. [Interpretation of the clinical practice guidelines for adult patients with IgA nephropathy and IgA vasculitis-associated nephritis in China (2025)].2025Zhonghua nei ke za zhi
  2. [The standardization process and clinical challenges in the diagnosis and treatment of IgA nephropathy in China:commentary on the clinical practice guidelines for adult patients with IgA nephropathy and IgA vasculitis-associated nephritis i2025Zhonghua nei ke za zhi
  3. [Immunomodulatory effects and research progresses of budesonide enteric-coated capsules in IgA nephropathy].2025Zhonghua nei ke za zhi
  4. [IgA nephropathy: current treatment status, prospects, opportunities, and challenges].2024Zhonghua nei ke za zhi
  5. [Clinical and genetic analysis of a child with co-morbid progressive IgA nephropathy and COQ8B-associated glomerulopathy].2024Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
早期论文(2016–2020 年)29
  1. Persistent Hematuria and Kidney Disease Progression in IgA Nephropathy: A Cohort Study.2020American journal of kidney diseases : the official journal of the National Kidney Foundation
  2. Effect of hydroxychloroquine in patients with IgA nephropathy with insufficient responses to immunosuppressive therapy: a retrospective case-control study.2020BMC nephrology
  3. Neutrophil-to-lymphocyte ratio as an independent inflammatory indicator of poor prognosis in IgA nephropathy.2020International immunopharmacology
  4. MicroRNA-21-5p participates in IgA nephropathy by driving T helper cell polarization.2020Journal of nephrology
  5. Variation in complement factor H affects complement activation in immunoglobulin A vasculitis with nephritis.2020Nephrology (Carlton, Vic.)
  6. Plasma galactose-deficient immunoglobulin A1 and loss of kidney function in patients with immunoglobulin A vasculitis nephritis.2020Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  7. Helicobacter pylori infection is associated with elevated galactose-deficient IgA1 in IgA nephropathy.2020Renal failure
  8. [Efficacy and safety of steroid combined with immunosuppressants in the treatment of primary IgA nephropathy in children: a Meta analysis].2020Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
  9. Microangiopathic Lesions in IgA Nephropathy: A Cohort Study.2019American journal of kidney diseases : the official journal of the National Kidney Foundation
  10. Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Randomized Controlled Trial.2019American journal of kidney diseases : the official journal of the National Kidney FoundationRCT
  11. Comparison of the effects of hydroxychloroquine and corticosteroid treatment on proteinuria in IgA nephropathy: a case-control study.2019BMC nephrology
  12. [Trans-ethnic analysis of susceptibility variants in IgA nephropathy].2019Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  13. Plasma Galactose-Deficient IgA1 and C3 and CKD Progression in IgA Nephropathy.2019Clinical journal of the American Society of Nephrology : CJASN
  14. Autophagy in Immune-Related Renal Disease.2019Journal of immunology research
  15. Urine afamin and afamin-creatinine ratio as biomarkers for kidney injury.2018Biomarkers in medicine
  16. Insights into the Role of Mucosal Immunity in IgA Nephropathy.2018Clinical journal of the American Society of Nephrology : CJASN
  17. Value of the Oxford classification of IgA nephropathy in children with Henoch-Schönlein purpura nephritis.2018Journal of nephrology
  18. Circulating complement factor H-related protein 5 levels contribute to development and progression of IgA nephropathy.2018Kidney international
  19. Update on treatment of immunoglobulin A nephropathy.2018Nephrology (Carlton, Vic.)
  20. Characteristics of patients with coexisting IgA nephropathy and membranous nephropathy.2018Renal failure
  21. Coding and Noncoding Variants in CFH Act Synergistically for Complement Activation in Immunoglobulin A Nephropathy.2018The American journal of the medical sciences
  22. Pathogenic role of glycan-specific IgG antibodies in IgA nephropathy.2017BMC nephrology
  23. Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.2017JAMARCT
  24. Mannose-Binding Lectin Levels Could Predict Prognosis in IgA Nephropathy.2017Journal of the American Society of Nephrology : JASN
  25. Dividing CKD stage 3 into G3a and G3b could better predict the prognosis of IgA nephropathy.2017PloS one
  26. Plasma Exchange as an Adjunctive Therapy for Crescentic IgA Nephropathy.2016American journal of nephrology
  27. Measures of Urinary Protein and Albumin in the Prediction of Progression of IgA Nephropathy.2016Clinical journal of the American Society of Nephrology : CJASN
  28. Elevated Plasma α-Defensins (HNP1-3) Levels Correlated with IgA1 Glycosylation and Susceptibility to IgA Nephropathy.2016Disease markers
  29. Rare Variants in the Complement Factor H-Related Protein 5 Gene Contribute to Genetic Susceptibility to IgA Nephropathy.2016Journal of the American Society of Nephrology : JASN
它在 ClinicalTrials.gov 上的全部试验(任何状态)30
  1. A Study of Hydroxychloroquine Sulfate for Reduction of Proteinuria in Patients With IgA Nephropathy已完成NCT02942381牵头方II期2016-09 启动
  2. Trial of Plasma Exchange for Severe Crescentic IgA Nephropathy已终止NCT02647255牵头方II/III期2016-03 启动
  3. Registry of IgA Nephropathy in Chinese Children状态不明NCT03015974牵头方2016-01 启动
  4. To Assess the Efficacy and Safety of Utilizing Galactose-deficient IgA1 Biomarker Changes to Guide Pathogenic IgA-targeted Therapeutic Strategies正在招募NCT07822100牵头方(推断)不分期2026-08 启动
  5. Hydroxychloroquine Sulfate for Reduction of Proteinuria in Patients With IgA Nephropathy: a Self- Controlled Study已完成NCT02351752牵头方(推断)IV期2015-01 启动
  6. Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN正在招募NCT07390123研究中心III期2026-04 启动
  7. A Trial to Evaluate the Long-term Safety and Tolerability of HRS-5965 in Patients With Primary IgA Nephropathy正在招募NCT07582133研究中心II期2026-07 启动
  8. A Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy.正在招募NCT07375758研究中心I/II期2026-02 启动
  9. Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular Diseases正在招募NCT07614477研究中心II期2026-05 启动
  10. A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy正在招募NCT06963827研究中心III期2025-07 启动
  11. A Trial of HRS-5965 Capsule in Primary IgA Nephropathy正在招募NCT07014826研究中心III期2025-06 启动
  12. A Study to Evaluate the Long-Term Safety and Efficacy of HSK39297 Tablets in Primary IgA Nephropathy正在招募NCT07616700研究中心II期2025-08 启动
  13. Clinical Study of CM338 in the Treatment of Immunoglobulin A Nephropathy正在招募NCT05775042研究中心II期2023-05 启动
  14. Phase II Clinical Study on the Efficacy and Safety of QLS7305 in Patients With Kidney Disease (Part A)即将招募NCT07730632研究中心II期2026-08 启动
  15. IBI3034 Study in Healthy Adults and Patients With Primary IgA Nephropathy即将招募NCT07886476研究中心I期2026-10 启动
  16. Efficacy and Safety Study of HS-10542 for IgA Nephropathy即将招募NCT07474636研究中心II期2026-03 启动
  17. A Study of SGB-9768 in Patients With Complement-mediated Kidney Diseases进行中,不再招募NCT06786338研究中心II期2025-06 启动
  18. Study of CM313 in Subject With IgA Nephropathy即将招募NCT06830395研究中心II期2025-09 启动
  19. A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA Nephropathy进行中,不再招募NCT07305974研究中心II期2025-09 启动
  20. A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases即将招募NCT06774664研究中心I/II期2025-01 启动
  21. Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN)即将招募NCT06687174研究中心II期2024-12 启动
  22. Phase II Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN已完成NCT06670352研究中心II期2024-10 启动
  23. A Phase IIa Study in Primary IgA Nephropathy Patients已完成NCT07634744研究中心II期2024-12 启动
  24. A Study of the Effect and Safety of HS-10390 in the Treatment of Patients with Primary IgA Nephropathy状态不明NCT06635772研究中心II期2024-11 启动
  25. A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression进行中,不再招募NCT05797610研究中心III期2023-08 启动
  26. A Study of Telitacicept for IgA Nephropathy (TELIGAN)进行中,不再招募NCT05799287研究中心III期2023-04 启动
  27. TESTING -ON Post-Trial ObservatioNal Cohort Study已完成NCT05434325研究中心2022-12 启动
  28. Atrasentan in Patients With IgA Nephropathy进行中,不再招募NCT04573478研究中心III期2020-12 启动
  29. A Study of RC18 Administered Subcutaneously to Subjects With Primary IgA(Immunoglobulin A) Nephropathy已完成NCT04291781研究中心II期2020-04 启动
  30. Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)已完成NCT01560052研究中心不分期2012-05 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

尼曼-匹克病 C 型

Niemann–Pick disease type C

2021–2025 年没有牵头尼曼-匹克病 C 型的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

北京有 3 家医院列在尼曼-匹克病 C 型下全国有 15 家医院列在尼曼-匹克病 C 型下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尼曼-匹克病 C 型开放试验。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Safety and Efficacy of Miglustat in Chinese NPC Patients已完成NCT03910621研究中心IV期2020-04 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性胆汁性胆管炎

Primary biliary cholangitis

2021–2025 年没有牵头原发性胆汁性胆管炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

北京有 16 家医院列在原发性胆汁性胆管炎下全国有 173 家医院列在原发性胆汁性胆管炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性胆汁性胆管炎开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性硬化性胆管炎

Primary sclerosing cholangitis

2021–2025 年中国大陆作者发表的 100 篇原发性硬化性胆管炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.0%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

北京有 10 家医院列在原发性硬化性胆管炎下全国有 90 家医院列在原发性硬化性胆管炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性硬化性胆管炎开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

先天性巨结肠

Hirschsprung disease

2021–2025 年中国大陆作者发表的 161 篇先天性巨结肠 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.6%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

北京有 8 家医院列在先天性巨结肠下全国有 82 家医院列在先天性巨结肠下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的先天性巨结肠开放试验。

这些数字背后的记录
论文中的科室儿科
牵头的论文1
  1. Electro-clinical features of Mowat-Wilson syndrome: A retrospective study of 31 children in mainland China.2026Epileptic disorders : international epilepsy journal with videotape
中文论文(未计入)1
  1. [Clinical features of epilepsy in 5 children with Mowat-Wilson syndrome].2022Zhonghua er ke za zhi = Chinese journal of pediatrics

打开 PubMed 检索ClinicalTrials.gov

其他疾病

遗传性大疱性表皮松解症

Inherited epidermolysis bullosa

2021–2025 年中国大陆作者发表的 56 篇遗传性大疱性表皮松解症 PubMed 英文论文中,这家医院牵头了 5 篇,占 8.9%。

牵头论文
5
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 2220232024: 1120242025: 002025

北京有 4 家医院列在遗传性大疱性表皮松解症下全国有 41 家医院列在遗传性大疱性表皮松解症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的遗传性大疱性表皮松解症开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

家族性腺瘤性息肉病

Familial adenomatous polyposis

2021–2025 年中国大陆作者发表的 59 篇家族性腺瘤性息肉病 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.7%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

北京有 7 家医院列在家族性腺瘤性息肉病下全国有 76 家医院列在家族性腺瘤性息肉病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的家族性腺瘤性息肉病开放试验。

这些数字背后的记录
牵头的论文1
  1. Global, regional, and national burdens of cirrhosis in children and adolescents aged under 19 years from 1990 to 2019.2024Hepatology international
早期论文(2016–2020 年)1
  1. [Concurrent APC and MLH1mutations identified in a family affected with familial adenomatous polyposis].2018Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

北京大学第一医院

Peking University First Hospital

北京

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请以上方链接的医院官方页面为准。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR Wikidata
Peking University First Hospital-Miyun Hospital; Beida Hospital

提出更正下载数据